8-K: Unicycive Therapeutics Receives Second Extension from Nasdaq to Regain Minimum Bid Price Compliance

Unicycive Therapeutics has been granted a second 180-day extension by Nasdaq to regain compliance with the minimum $1.00 per share bid price requirement.

Summary

• Unicycive Therapeutics received a notice from Nasdaq on July 9, 2024, stating that its stock price had fallen below the required $1.00 minimum for 30 consecutive days.
• The company was initially given 180 days, until January 6, 2025, to regain compliance.
• As of January 6, 2025, Unicycive had not regained compliance with the minimum bid price requirement.
• On January 7, 2025, Nasdaq granted Unicycive an additional 180 days, until July 7, 2025, to meet the minimum bid price requirement.
• Unicycive intends to monitor its stock price and consider options to regain compliance.

Sentiment

Score: 3

Explanation: The document indicates a negative situation with the company's stock price falling below the minimum requirement, although a second extension provides some relief.

Positives

• Unicycive has been granted a second extension by Nasdaq, providing more time to regain compliance.

Negatives

• Unicycive's stock price has been below the minimum $1.00 requirement for an extended period.
• The company failed to regain compliance within the initial 180-day period.

Risks

• Failure to regain compliance by July 7, 2025, could result in delisting from the Nasdaq Capital Market.
• The company's stock price may continue to be volatile.

Future Outlook

Unicycive intends to monitor its stock price and consider options to regain compliance with Nasdaq listing rules.

Management Comments

• The company intends to actively monitor the closing bid price of its Common Stock and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price under the Nasdaq Listing Rules.

Industry Context

This situation is not uncommon for companies listed on the Nasdaq Capital Market, which has specific requirements for minimum stock prices to maintain listing status. Many companies face similar challenges and must take action to avoid delisting.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining minimum bid prices on exchanges like Nasdaq.
• Companies like Athersys and Ocugen have also faced delisting warnings due to low stock prices.
• The 180-day extension is a standard procedure for companies in this situation, and Unicycive's situation is not unique.

Stakeholder Impact

• Shareholders may be concerned about the potential for delisting.
• The company's ability to raise capital may be affected by the low stock price.

Next Steps

• Unicycive will monitor its stock price.
• Unicycive may consider options to regain compliance with Nasdaq listing rules.

Key Dates

Keywords

Nasdaq, minimum bid price, compliance, stock price, delisting, UNCY, Unicycive Therapeutics